FN1 and cancer: To assess whether mifepristone impairs the capacity of cancer cells to adhere to extracellular matrix, cells were pre-treated for 72 h with or without a cytostatic concentration of mifepristone, trypsinized, and re-plated in commercially available plates that had been pre-coated with an array of extracellular matrix proteins including fibronectin, collagen I, collagen IV, laminin or fibrinogen.